Soft Transport BioSystem Inc.

STB is driven to develop versatile artificial viruses (i.e., synthetic virus-like nanoparticles; non-viral vectors) that serve as an ideal alternative to viral vectors for targeted delivery of therapeutic cargos (e.g., plasmid DNA, siRNA, shRNA, CRISPR/Cas9). Unlike viral vectors that have several drawbacks including immunogenicity, cytotoxicity, biosafety requirements for handling infectious material, laborious production procedures, and high costs, our patent-pending delivery technology offers safe, potent, easy-to-use, and cost-effective delivery systems that can efficiently and effectively deliver cargos in a site-specific manner for in vitro molecular biology applications as well as ex vivo and in vivo gene therapies.